ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2191

Intravenous Sodium Thiosulfate for Treatment of Refractory Calcinosis in Rheumatic Disease

Ross Thibodaux1, Bahnsen Miller1 and Stephen Lindsey2,3, 1Internal Medicine, Louisiana State University Health Science Center, Baton Rouge, LA, 2Chief Div of Rheumatology, Ochsner Clinic Baton Rouge, Baton Rouge, LA, 3Internal Medicine - Rheumatology, Louisiana State University Health Science Center, Baton Rouge, LA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: calcinosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Calcinosis, or dystrophic calcification, is a poorly understood, debilitating condition commonly manifested in connective tissue diseases such as scleroderma and polymyositis. Despite treatment of the rheumatologic disease, patients typically endure pain, infections, and decreased joint mobility. Therapeutic options for calcinosis, including coumadin, corticosteroids, diltiazem, probenecid, and colchicine, have shown little success, and treatment failure is common. Intravenous sodium thiosulfate (IV STS) is commonly used to treat calciphylaxis, and several mechanisms are proposed for its effects. Intriguingly, the chelating properties of IV STS form water soluble calcium-thiosulfate, which aids in dissolving deposited calcium salts. Additionally, STS increases production of glutathione and nitric oxide, which improve endothelial function, vasodilate blood vessels, and decrease tissue ischemia. Physiologically, it is feasible to hypothesize that IV STS may treat refractory calcinosis, but data is not available regarding its use. The following patient chart reviews illustrate this hypothesis:

Methods:

Patients #1, a 63 yo Caucasian female with limited scleroderma, and #2, a 46 yo Black female with polymyositis, suffer with recurrent calcinosis deposits of the skin and soft tissue causing pain and functional loss. Patient #1 reported severe pain and decreased mobility of her hands, and patient #2 reported deposits in her posterior thigh causing severe pain on sitting down and standing up. Aggressive therapy, including corticosteroids, colchicine, calcium channel blockers, and surgical interventions, yielded little improvement in pain and function. Each patient regularly reported pain scores of 8-9/10.  After discussing IV STS therapy and obtaining consents, infusions were started at 12.5 grams over one hour weekly and advanced as tolerated. The maximum doses achieved in patients #1 and #2 were 15 gm/week and 25 gm/week, respectively. Infusions were continued weekly for approximately seven months. The infusions were tolerated well, and the most common patient reported side effects were nausea and blurry vision. The most common laboratory abnormality was a non-gap metabolic acidosis.

Results:

As early as two weeks after starting the infusions, improvements in pain scores and softening of calcinosis deposits were observed. Both patients reported improved pain scores of 3-4/10 at two weeks and 0-1/10 at four weeks, and this persisted throughout therapy. At four weeks, functional status improved; specifically, patient #1 was able to grip a drinking glass without difficulty, and patient #2 was able to sit and stand with ease.

Conclusion:

The clinical improvements observed may be attributed to the inherent properties of IV STS. Intravenous STS therapy is approved for calciphylaxis as well as cyanide and chemo-related toxicities. Although calcinosis is pathologically different from calciphylaxis, the physiologic properties of IV STS may contribute to the clinical improvements outlined above. These findings illustrate the potential of IV STS to treat painful calcinosis and the need for further studies of its use in rheumatic disease.


Disclosure:

R. Thibodaux,
None;

B. Miller,
None;

S. Lindsey,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/intravenous-sodium-thiosulfate-for-treatment-of-refractory-calcinosis-in-rheumatic-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology